The American Academy of Neurology (AAN) Annual Meeting 2025 took place in San Diego, California on April 5-9, 2025.
This prestigious gathering served as a pivotal platform for neurological advancements, featuring 1,272 total presentations, including 215 industry-sponsored sessions. The conference provided crucial insights into emerging therapies, clinical trial outcomes, and evolving treatment paradigms across key neurological conditions.
Among the major pharmaceutical players, UCB dominated with the highest share of voice, followed by Biohaven, Pfizer, and Biogen. Epilepsy, migraine, multiple sclerosis, and Alzheimer’s disease emerged as the most prominently featured therapeutic areas.
Multiple Sclerosis breakthroughs
Sanofi presented promising Phase III results for tolebrutinib, a potential first-in-class BTK inhibitor for progressive MS. The HERCULES trial demonstrated significant effects on disability progression in non-relapsing secondary progressive MS patients. Meanwhile, Roche/Genentech focused on ocrelizumab safety data in pregnancy and breastfeeding, supporting recent European label changes.
Myasthenia gravis pipeline advances
The myasthenia gravis landscape appears poised for transformation with Phase III data presentations from Johnson & Johnson’s nipocalimab and RemeGen’s telitacicept. Both therapies showed meaningful improvements in MG-ADL and QMG scores, addressing critical unmet needs for patients with various antibody profiles.
Migraine treatment competition
Competition in the acute migraine space intensified as Axsome Therapeutics presented comparative efficacy data for recently approved Symbravo (AXS-07) against gepants. Pfizer continued strengthening Nurtec/Vydura’s position with multiple real-world studies showing higher treatment satisfaction and persistence compared to triptans. Lundbeck presented long-term data for Vyepti (eptinezumab), highlighting sustained response rates.
Alzheimer’s disease insights
Following major data releases at the ADPD 2025 conference, AAN presentations focused on Axsome’s Auvelity (AXS-05) for Alzheimer’s agitation, with positive Phase III results showing a significant delay in agitation relapse. Multiple real-world studies of Eisai/Biogen’s Leqembi (lecanemab) provided insights into treatment persistence, safety profiles, and outcomes in broader patient populations.
The meeting highlighted the neurological therapeutic landscape’s continued evolution, with increasing competition in established markets and breakthrough therapies addressing long-standing unmet needs across multiple neurological conditions.
